The FDA has approved Opdivo Qvantig (nivolumab and hyaluronidase-nvhy), a new subcutaneous injection formulation of Opdivo.
EXEL's shares surge 50% in a year on the back of the strong performance of its lead drug Cabometyx. We are optimistic about ...
If you're worried about having enough passive income to maintain your lifestyle during retirement, you're not alone. Filling your portfolio with dividend-paying stocks that raise their quarterly ...
Halozyme provides subcutaneous drug delivery solutions, with several major new products recently approved. Click here to find ...
The U.S. Food and Drug Administration has approved Opdivo Qvantig (nivolumab and hyaluronidase-nvhy) injection for ...
On December 20, 2024, the FDA granted accelerated approval to the combination of encorafenib (Braftovi), cetuximab (Erbitux), ...
FDA officials have set a review date of June 30, 2025, to review avutometinib in combination with defactinib to treat ...
FDA approves the first subcutaneous version of nivolumab, making PD-1 inhibitors available to new groups of patients.
The agency’s main drug review office cleared 50 novel medicines last year, short of 2018’s record total but on the higher end ...
Regulators squeezed in two final approvals before the calendar change with the UK approval of Merck’s Winrevair and the FDA’s ...
Almost exactly 10 years after the FDA’s initial FDA approval for Bristol Myers Squibb’s Opdivo as the first PD-1 inhibitor in ...
The top 10 patented drugs getting expired in the coming years in the US, include Pembrolizumab, sold under the brand name ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback